Vimarsana
Biggest News Aggregation in the World

Junj Yang News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Junj Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Junj Yang Today - Breaking & Trending Today

Novel therapeutic approach identified for overcoming resistance in B-cell leukemia - Vimarsana News

Novel therapeutic approach identified for overcoming resistance in B-cell leukemia

Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between 30-50%.

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match - Vimarsana News

Next Frontier of Precision Hematology Uses Patient Tissue to Find a Therapy Match

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Source: ajmc.com
DNA Index Most Effectively Identifies Patients With Hyperdiploid ALL - Vimarsana News

DNA Index Most Effectively Identifies Patients With Hyperdiploid ALL

The measure of total DNA in leukemic cells as defined by a DNA index outperformed other criteria for identifying patients with hyperdiploid acute lymphoblastic leukemia (ALL) and favorable prognosis.

Source: ajmc.com
St. Jude Children's researchers better define hyperdiploidy in childhood B-ALL - Vimarsana News

St. Jude Children's researchers better define hyperdiploidy in childhood B-ALL

Hyperdiploidy is a genetic condition observed in cancer cells, where the cells contain more chromosomes than usual.

Study describes the variations in drug response across genetic subtypes of childhood leukemia - Vimarsana News

Study describes the variations in drug response across genetic subtypes of childhood leukemia

Scientists at St. Jude Children's Research Hospital are reporting the most comprehensive study to date describing the variations in drug response across different genetic subtypes of acute lymphoblastic leukemia (ALL).